Anaptysbio Inc Revenue Growth Rates (ANAB), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Anaptysbio Inc   (NASDAQ: ANAB)
 

ANAB's Revenue Growth by Quarter and Year

Anaptysbio Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ANAB/growth
https://api.csimarket.com/api/v1/companies/ANAB/fundamentals
https://api.csimarket.com/api/v1/companies/ANAB/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ANAB Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September 30.27
FY 30.27

ANABs Annual Revenue
Anaptysbio Inc 's Revenue in the fiscal year 2025 $ 234.60 millions
Anaptysbio Inc 's Revenue in the fiscal year 2024 $ 91.28 millions
Anaptysbio Inc 's Revenue in the fiscal year 2023 $ 17.16 millions
Anaptysbio Inc 's Revenue in the fiscal year 2022 $ 10.29 millions
Anaptysbio Inc 's Revenue in the fiscal year 2021 $ 63.18 millions




ANAB Revenue first quarter 2026 Y/Y Growth Comment
Anaptysbio Inc reported Revenue improvement of 36% year on year in the first quarter 2026, to $ 30.27 millions, this is lower than Anaptysbio Inc 's recent average Revenue surge of 140.73%.

Looking into first quarter 2026 results within Major Pharmaceutical Preparations industry 48 other companies have achieved higher Revenue growth. While Anaptysbio Inc ' s Revenue rise of 36% ranks overall at the positon no. 456 in the first quarter 2026.


ANAB Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September 36 %
FY   -

Financial Statements
Anaptysbio Inc 's first quarter 2026 Revenue $ 30.27 millions ANAB's Income Statement
Anaptysbio Inc 's first quarter 2025 Revenue $ 22.26 millions Quarterly ANAB's Income Statement


ANAB Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter June -
3rd Quarter March -
2nd Quarter December -
1st Quarter September 18.44 %
FY (Year on Year)   -


Back to ANAB Growth rate Comparisons >> Back to ANAB Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #49
Healthcare Sector #104
Overall #456

Revenue Y/Y Growth Statistics
High Average Low
432.03 % 140.73 % -96.32 %
(Dec 31 2024)   (Sep 30 2022)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #49
Healthcare Sector #104
Overall #456
Revenue Y/Y Growth Statistics
High Average Low
432.03 % 140.73 % -96.32 %
(Dec 31 2024)   (Sep 30 2022)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Anaptysbio Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
426.53 % 52.34 % -100 %
(Dec 31 2022)  


ANAB's I. Quarter Q/Q Revenue Comment
Anaptysbio Inc achieved in the I. Quarter 2026 below company average Revenue jump of 18.44% quarter on quarter, to $ 30.27 millions.

I. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -19.84% in the I. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 132 other companies have achieved higher Revenue quarter on quarter growth. While Anaptysbio Inc 's Revenue growth quarter on quarter, overall rank is 2722.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #133
Healthcare Sector #377
Overall #2722
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #133
Healthcare Sector #377
Overall #2722
Revenue Q/Q Growth Statistics
High Average Low
426.53 % 52.34 % -100 %
(Dec 31 2022)  


ANAB's I. Quarter Q/Q Revenue Comment
Anaptysbio Inc achieved in the I. Quarter 2026 below company average Revenue jump of 18.44% quarter on quarter, to $ 30.27 millions.

I. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -19.84% in the I. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 132 other companies have achieved higher Revenue quarter on quarter growth. While Anaptysbio Inc 's Revenue growth quarter on quarter, overall rank is 2722.


Anaptysbio Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 240.40
Y / Y Revenue Growth (TTM) 95.19 %
Year on Year Revenue Growth Overall Ranking # 28
Seqeuential Revenue Change (TTM) 3.45 %
Seq. Revenue Growth (TTM) Overall Ranking # 456


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Anaptysbio Inc 's cumulative twelve months Revenue were $ 240 millions, company would post below average annual Revenue growth of 3.45% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Anaptysbio Inc 's Revenue growth from the 25.56% growth in Mar 31 2026.

Among companies within the Healthcare sector 11 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 14 to 28.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 49
Healthcare Sector # 12
Overall # 28

Revenue TTM Y/Y Growth Statistics
High Average Low
432.03 %
 140.73 %
-96.32 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 49
Sector # 104
S&P 500 # 456
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2026 period, Anaptysbio Inc 's cumulative twelve months Revenue were $ 240 millions, company would post below average annual Revenue growth of -96.32% year on year, if the fiscal year would end at Sep 30 2026.
A slow-down in the Anaptysbio Inc 's Revenue growth from the 25.56% growth in Mar 31 2026.

Among companies within the Healthcare sector 11 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 14 to 28.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 49
Healthcare Sector # 12
Overall # 28

Revenue TTM Y/Y Growth Statistics
High Average Low
432.03 %
140.73 %
-96.32 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 49
Sector # 104
S&P 500 # 456




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ANAB's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Tg Therapeutics Inc 60.74%$ 60.743 millions
Therapeuticsmd Inc 60.59%$ 60.587 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Yunhong Green Cti Ltd 51.28%$ 51.282 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions
Immucell Corporation49.91%$ 49.912 millions
Hims and Hers Health Inc 48.88%$ 48.877 millions
Maxcyte inc 48.66%$ 48.660 millions
Billiontoone Inc 47.43%$ 47.431 millions
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions
Cardiff Oncology Inc 42.50%$ 42.500 millions
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions
Uniqure N v 40.39%$ 40.394 millions
Harrow Inc 40.00%$ 40.001 millions
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions


About Anaptysbio Inc Revenue Growth Rates (ANAB), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Anaptysbio Inc (CIK 1370053).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-458494
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Anaptysbio Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.